Clinical Trial Update: Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports on the safety, tolerability, and pharmacokinetics of PRA-027 administered to women of nonchildbearing potential with uterine f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• PRA-027

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Fibroid | Phase 1 | Status: COMPLETED